BACKGROUND
==========

The prevalence of paediatric obesity has increased over the last decades in many countries, with estimates indicating higher obesity prevalence among adolescents in the Eastern Mediterranean Region (EMRO) than that reported from Europe and the US ([@b24]). The increase in the prevalence of obesity in youths has been parallelled by an increase in the prevalence of paediatric metabolic syndrome (MS), a constellation of metabolic risk factors that include insulin resistance, hypertension, glucose intolerance and an abnormal lipid profile ([@b43]; [@b15]; [@b3]). A recent study conducted in Turkey showed that, among 2--19 year old children and adolescents, a one-point increase in BMI *Z*-score resulted in a 2-fold increase in the prevalence of MS ([@b34]).

Based on the modified ATPIII criteria ([@b8]), prevalence estimates of MS among obese adolescents were found to vary between 18% in Spain and 42% in the US, suggesting an ethnic-based association between obesity and MS ([@b30]; [@b12]). Limited data from the Middle-East suggest high rates of MS and cardiometabolic risk factors in the adolescent population. The prevalence of MS among obese adolescents in Iran is among the highest estimates reported in the literature (41.9%) ([@b15]). Similarly, in a recent study conducted on 203 overweight and obese subjects aged 6--17 years living in Norway, the prevalence of MS was found to be higher among obese subjects with Middle Eastern origins than among their Norwegian counterparts (30.6% vs 20.8%) ([@b26]). This association between adolescent obesity and MS indicators has not been investigated in many countries of the Middle-East.

Although recent definitions of MS do not include direct measurement of insulin in children ([@b16]), insulin resistance (IR) has been frequently reported to overlap with MS and to confer cardiometabolic disease risk distinct from that attributed to MS itself ([@b18]; [@b12]; [@b38]). Ethnic disparities in insulin resistance have also been reported in the literature, with insulin resistance suggested as being more frequent in White and African-American people and less common in Asiatic, Arabic and Latin American populations ([@b4]).

Even though the clinical utility of MS as a disease category faces considerable controversy, particularly when applied to the paediatric population, the screening for MS and its components early in life allows for the identification of individuals at significant risk for cardiovascular disease and those in urgent need of lifestyle intervention. Recent evidence suggests the presence of early functional and morphologic changes to the heart and blood vessels among obese adolescents with MS ([@b7]). Yet, the plasticity of the cardiovascular system early in life allows for the reversal of cardiovascular damage and cardiac abnormalities in obese adolescents, but only if risks are identified early and treated aggressively ([@b20]; [@b2]). For these reasons, the identification of paediatric MS in individuals who have not yet developed cardiovascular disease, is of great importance from a public health perspective.

This study was conducted to investigate the magnitude of the association between obesity, insulin resistance and various components of the MS among adolescents (Tanner stages 4--5) in Lebanon, a small Eastern Mediterranean country, where prevalence rates of paediatric obesity are high, approaching those observed in developed countries such as the US ([@b36]).Confirming MS prevalence in Lebanese obese adolescents should lead to multi-component interventions targeting MS and its components in Lebanon and other parts of the Middle-East.

METHODS
=======

Study design and participants
-----------------------------

This is a cross-sectional study of adolescents attending public schools in Beirut. The research was approved by the Institutional Review Board, American University of Beirut.

A sample of 263 subjects was recruited using a multistage cluster sampling as follows. Out of 74 public schools in Beirut, eight were randomly selected from the list of the Lebanese Ministry of Education. From grades 10, 11 and 12, a BMI-stratified sample was conveniently recruited. Stratification was based on BMI status as defined by the new WHO growth standards ([@b11]). Accordingly, obesity was defined as BMI \> +2 *Z*-scores for sex and age, overweight as + 1 \< BMI *Z*-scores ≤ + 2 and normal weight as BMI ≤ + 1 BMI *Z*-scores ([@b11]). Written informed consent from parents and written informed assent from participants was sought. Subjects were invited to visit the research centre at the Nutrition and Food Science Department at the American University of Beirut and were instructed to consume a daily diet providing 50--60% of energy intake as carbohydrates for 3 days prior to their visit and to avoid any vigorous physical activity. Eligibility of study subjects was verified. Subjects were eligible if they were healthy, at 4^th^ and 5^th^ Tanner stages of puberty, as determined by a medical doctor, and of Lebanese ancestry. Exclusion criteria included history of chronic illness or the use of medications that alter blood pressure, glucose or lipid metabolism.

Sample size calculation was based on the following: To detect a moderate correlation (*r*) of a range of 0.2--0.3 between obesity and components of the metabolic syndrome, a sample of 68--150 subjects was needed to provide an 80% power at *p* = 0.05.

Data collection
---------------

Data collection was carried out in 2008 -- 2009 on participants who matched inclusion criteria and had provided written assent as well as parental written informed consent. Anthropometric measurements were taken after voiding and included weight, height, WC and %BF which was measured by dual-energy X-ray absorptiometry (DXA) (Delphi W, Hologic Inc, QDR software for windows version 11.2) based on region %BF. Waist circumference (WC) was measured using a calibrated plastic measuring tape, at the umbilicus level, with subjects standing and following normal expiration ([@b31]). Fasting blood samples (10 ml/participant) were obtained by a phlebotomist for the analysis of serum glucose, insulin, triglycerides (TG) and HDL. Blood pressure was measured by a registered nurse using a mercury sphygmomanometer, with the subjects seated and after a 5-minute rest.

Biochemical analysis
--------------------

Plasma glucose was analysed using the COBAS 6000 analyzer (Roche Diagnostics, Switzerland). Serum insulin was determined by the use of an antibody radioimmunoassay kit (Linco Research, Missouri, USA). Serum TG was determined using the COBAS 6000 analyzer (Roche Diagnostics, Switzerland) while serum HDL was colourimetrically determined by the use of the HDL separation tab (Union Carbide Corp. Pleasantville, NY, USA).

Diagnostic criteria for the metabolic syndrome
----------------------------------------------

MS was defined based on the recently published harmonized metabolic syndrome definition ([@b1]), according to which three abnormal findings out of five would qualify the subject for the MS. The cut-off values for the individual metabolic abnormalities are based on the IDF criteria ([@b45]), which recommend the use of the adult IDF cut-off values for subjects aged 16 years and older, as follows: abdominal obesity (WC s 94 cm for males and s 80 cm for females); elevated TG (≥ 150 mg/dL); low levels of HDL (\< 40 mg/dL for males and \< 50 mg/dL for females); high systolic blood pressure (SBP) (≥ 130 mmHg) or high diastolic blood pressure (DBP) (≥ 85 mmHg); high fasting glucose (≥ 100 mg/dL). For subjects aged 10--16 years, the IDF recommends the use of the same diagnostic criteria except for WC and HDL, where WC ≥ 90^th^ percentile for age and sex, and HDL \< 40 mg/dL were used as cut-off values. For comparative purposes, the data were also analysed according to the modified ATP III definition ([@b8]).

As reference values specific for adolescents in Lebanon are not available, hyperinsulinemia was determined based on cut-off points specific for the Tanner stage of maturation (fasting insulin ≥ 30 mlU/L for Tanner stage 4; fasting insulin ≥ 20 mlU/L for Tanner stage 5) proposed by the literature ([@b17]; [@b34]). Insulin resistance (IR) was determined using the homeostatic model assessment of insulin resistance (HOMA-IR) defined as: Values exceeding 3.16 indicated the presence of IR ([@b25]).

Statistical analysis
--------------------

Statistical analysis was performed using the Statistical Analysis Package for Social Sciences (SPSS, version 16.0) and the level of significance was set at *p* \< 0.05. Frequencies and descriptive statistics were performed for the different variables under study including MS prevalence according to different definitions as well as the prevalence of individual components of MS. Means and standard deviations were computed for anthropometric and biochemical variables. Mean differences were compared for significance between groups, using one-way ANOVA. Pearson correlations were performed between obesity indicators and the different MS components. The association between MS abnormalities (dependant variables) and adiposity indicators including %BF, WC and BMI (independent variables) was assessed by age and sex- adjusted linear regression analyses. Natural logarithm transformation was performed when the dependent variable was not normally distributed. Determinants of MS were evaluated using age- and sex-adjusted logistic regression analysis.

RESULTS
=======

The study sample consisted of 263 adolescents (112 males and 151 females) and included 104 obese, 78 overweight and 81 normal weight subjects. Anthropometric, biochemical and blood pressure measurements of the study subjects are shown in [Table I](#tbl1){ref-type="table"}. Genders combined, mean serum TC, LDL-C, TG, insulin levels, systolic and diastolic blood pressure were significantly higher and HDL-C significantly lower in obese as compared to normal weight adolescents. The most common abnormality among obese adolescents was elevated WC (90.4%), followed by IR (88.5%) and hyperinsulinemia (73.1%), while hyperglycemia was the least common abnormality (3.8%) ([Table II](#tbl2){ref-type="table"}).

###### 

Baseline characteristics of the adolescent subjects.

                                                   Adolescents                                                                                       
  ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------
  Age (years), mean ± SD                           16.07 ± 1.30                                     16.39 ± 1.44                                     16.80 ± 1.27
  Anthropometric data, mean ± SD                                                                                                                     
   BMI (Kg/m^2^)                                   32.52 ± 3.39[a](#tf1-1){ref-type="table-fn"}     26.38 ± 1.35[b](#tf1-2){ref-type="table-fn"}     20.87 ± 1.98[c](#tf1-3){ref-type="table-fn"}
   Body Fat (DXA) (%)                              38.86 ± 5.65[a](#tf1-1){ref-type="table-fn"}     32.95 ± 7.29[b](#tf1-2){ref-type="table-fn"}     23.60 ± 8.76[c](#tf1-3){ref-type="table-fn"}
   WC (cm)                                         97.86 ± 11.57[a](#tf1-1){ref-type="table-fn"}    85.16 ± 8.95[b](#tf1-2){ref-type="table-fn"}     73.06 ± 8.38[c](#tf1-3){ref-type="table-fn"}
  Biochemical and blood pressure data, mean ± SD                                                                                                     
   TC (mg/dL)                                      156.78 ± 27.34[a](#tf1-1){ref-type="table-fn"}   154.19 ± 30.44[a](#tf1-1){ref-type="table-fn"}   141.63 ± 21.92[b](#tf1-2){ref-type="table-fn"}
   HDL (mg/dL)                                     43.66 ± 10.52[a](#tf1-1){ref-type="table-fn"}    46.80 ± 10.33[b](#tf1-2){ref-type="table-fn"}    48.10 ± 9.98[b](#tf1-2){ref-type="table-fn"}
   LDL (mg/dL)                                     93.84 ± 25.74[a](#tf1-1){ref-type="table-fn"}    90.60 ± 26.72[a](#tf1-1){ref-type="table-fn"}    79.86 ± 18.69[b](#tf1-2){ref-type="table-fn"}
   TG (mg/dL)                                      105.09 ± 50.39[a](#tf1-1){ref-type="table-fn"}   85.58 ± 42.76[b](#tf1-2){ref-type="table-fn"}    68.31 ± 26.05[c](#tf1-3){ref-type="table-fn"}
   FBG (mg/dL)                                     88.62 ± 8.10[a](#tf1-1){ref-type="table-fn"}     88.62 ± 7.11[a](#tf1-1){ref-type="table-fn"}     89.46 ± 5.48[a](#tf1-1){ref-type="table-fn"}
   Insulin (μU/mL)                                 33.55 ± 18.37[a](#tf1-1){ref-type="table-fn"}    26.42 ± 14.38[b](#tf1-2){ref-type="table-fn"}    10.64 ± 7.89[c](#tf1-3){ref-type="table-fn"}
   SBP (mmHg)                                      117.38 ± 11.97[a](#tf1-1){ref-type="table-fn"}   113.08 ± 9.98[b](#tf1-2){ref-type="table-fn"}    113.65 ± 10.41[b](#tf1-2){ref-type="table-fn"}
   DBP (mmHg)                                      70.67 ± 8.16[a](#tf1-1){ref-type="table-fn"}     66.99 ± 6.95[b](#tf1-2){ref-type="table-fn"}     65.33 ± 5.44[b](#tf1-2){ref-type="table-fn"}

Values in the same row with different superscripts are significantly different *p* \< 0.05 (one-way ANOVA between normal weight vs overweight vs obese groups).

Values in the same row with different superscripts are significantly different *p* \< 0.05 (one-way ANOVA between normal weight vs overweight vs obese groups).

Values in the same row with different superscripts are significantly different *p* \< 0.05 (one-way ANOVA between normal weight vs overweight vs obese groups).

The definitions of overweight and obesity were based on sex- and age-specific +1 and +2 BMI *z*-scores, respectively, derived from WHO child growth standards ([@b11]).

DBP, Diastolic Blood Pressure; FBG, Fasting Blood Glucose; HDL-C, High Density Lipoprotein-Cholesterol; SBP, Systolic Blood Pressure; TC, Total Cholesterol; TG, Triglycerides; WC, waist circumference.

###### 

Prevalence of individual metabolic abnormalities by BMI classification.

                                                                 Adolescents, *n* (%)               
  -------------------------------------------------------------- ---------------------- ----------- -----------
  Elevated Waist Circumference[a](#tf2-1){ref-type="table-fn"}   94 (90.4)              36 (46.2)   3 (3.7)
  Low HDL[a](#tf2-1){ref-type="table-fn"}                        45 (43.3)              29 (37.2)   27 (33.3)
  High tryglycerides[a](#tf2-1){ref-type="table-fn"}             21 (20.2)              6 (7.7)     1 (1.2)
  Hypertension[a](#tf2-1){ref-type="table-fn"}                   18 (17.3)              5 (6.4)     9(11.1)
  High fasting glucose[a](#tf2-1){ref-type="table-fn"}           4 (3.8)                6 (7.7)     3 (3.7)
  Insulin resistance[b](#tf2-2){ref-type="table-fn"}             92 (88.5)              66 (83.3)   20 (24.7)
  Hyperinsulinemia[c](#tf2-3){ref-type="table-fn"}               76 (73.1)              45 (57.7)   7 (8.6)

As defined by IDF Criteria:

• Elevated Waist Circumference (WC): For subjects 16 years and older, WC ≥ 94cm for males and ≥ 80 cm for females. For ages 13--15 years, WC ≥ 90th percentiles or adult cut-off value if lower;

• Low HDL: For subjects 16 years and older HDL \< 40 mg/dL for males and \< 50 mg/dL for females. For ages 13--15 years, HDL \< 40 mg/dL;

• High TG: TG ≥ 150 mg/dL;

• Hypertension: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; and

• High Fasting Glucose: ≥ 100 mg/dL.

Insulin resistance, HOMA-IR \> 3.16;

Hyperinsulinemia, Insulin ≥ 30 μU/ml for Tanner stage 4 and ≥ 20 μU/ml for Tanner stage 5.

The number of metabolic abnormalities increased with obesity ([Table III](#tbl3){ref-type="table"}), whereby 19.2% of obese subjects had three metabolic abnormalities as compared to 3.8% of overweight subjects and 1.2% of the normal weight subjects. The presence of four metabolic abnormalities was only noted among obese subjects (1.9%). Based on IDF criteria, the prevalence of MS was 21.2% in obese subjects, 3.8% in overweight subjects and 1.2% in the normal weight subjects. Analysing the data according to the modified ATP III definition ([@b8]) yielded a slightly higher prevalence of MS in the obese study sample (24.0%), while MS prevalence among overweight and normal weight subjects remained essentially the same (3.8% in overweight and 1.2% in normal weight subjects). Gender disparities were noted with both the IDF (27.1% in obese boys and 16.1% in obese girls) and ATPIII (31.3% in obese boys and 17.9% in obese girls) definitions, with obese boys showing higher prevalence rates of MS.

###### 

Number of metabolic syndrome abnormalities, according to IDF 2009 criteria.

                       Adolescents, *n* (%)               
  -------------------- ---------------------- ----------- -----------
  One                  44 (42.3)              33 (42.3)   32 (39.5)
  Two                  35 (33.7)              20 (25.6)   4 (4.9)
  Three                20 (19.2)              3 (3.8)     1 (1.2)
  Four                 2 (1.9)                0 (0.0)     0 (0.0)
  Metabolic syndrome   22 (21.2)              3 (3.8)     1 (1.2)

Among subjects having the MS, the most common metabolic abnormalities as defined by the IDF were elevated waist circumference (96.2%) and low HDL (96.2%) followed by hypertriglyceridemia (73.1%), while the least common metabolic abnormality was hyperglycaemia (7.7%) ([Table IV](#tbl4){ref-type="table"}).

###### 

Individual abnormalities among subjects with metabolic syndrome (*n* = 26), according to IDF (2009).

  Individual abnormalities                               Subjects with the metabolic syndrome, *n* (%)
  ------------------------------------------------------ -----------------------------------------------
  Elevated WC[a](#tf4-1){ref-type="table-fn"}            25 (96.2)
  Low HDL[a](#tf4-1){ref-type="table-fn"}                25 (96.2)
  High TG[a](#tf4-1){ref-type="table-fn"}                19 (73.1)
  Hypertension[a](#tf4-1){ref-type="table-fn"}           9 (34.6)
  High fasting glucose[a](#tf4-1){ref-type="table-fn"}   2 (7.7)
  Insulin resistance[b](#tf4-2){ref-type="table-fn"}     26 (100.0)
  Hyperinsulinemia[c](#tf4-3){ref-type="table-fn"}       19 (73.1)

As defined by IDF Criteria:

• Elevated Waist Circumference (WC): For subjects 16 years and older, WC ≥ 94 cm for males and ≥ 80 cm for females. For ages 13--15 years, WC ≥ 90th percentiles or adult cut-off value if lower.

• Low HDL: For subjects 16 years and older HDL \< 40 mg/dL for males and \< 50 mg/dL for females. For ages 13--15 years, HDL \< 40 mg/dL;

• High TG: TG ≥ 150 mg/dL;

• Hypertension: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; and

• High Fasting Glucose: ≥ 100 mg/dL.

Insulin resistance, HOMA-IR \> 3.16;

Hyperinsulinemia, Insulin ≥ 30 μU/ml for Tanner stage 4 and ≥ 20 μU/ml for Tanner stage 5.

IR was identified in 88.5% of obese, 84.6% of overweight and 24.7% of normal weight adolescents ([Table II](#tbl2){ref-type="table"}). Similarly, IR and hyperinsulinemia were present in 100% and 73.1% of subjects diagnosed with MS, respectively ([Table IV](#tbl4){ref-type="table"}).

Correlation analysis showed that, among subjects of both genders, both BMI and WC were significantly negatively correlated with HDL and significantly positively correlated with TG, SBP, DBP and insulin levels, while %BF was positively associated with TG, DBP, insulin levels and IR ([Table V](#tbl5){ref-type="table"}).

###### 

Pearson correlation coefficients of metabolic variables under study in subjects of both genders.

  Variable          \% BF   BMI     WC                                         HDL                                       TG                                          Glucose                                     SBP                                        DBP                                        Insulin                                     HOMA
  ----------------- ------- ------- ------------------------------------------ ----------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------- ------------------------------------------
  \% BF             1.000   0.726   0.453                                      0.049                                     0.299[\*\*](#tf5-2){ref-type="table-fn"}    −0.163[\*\*](#tf5-2){ref-type="table-fn"}   0.011                                      0.130[\*](#tf5-1){ref-type="table-fn"}     0.465[\*\*](#tf5-2){ref-type="table-fn"}    0.232[\*\*](#tf5-2){ref-type="table-fn"}
  *p*-value         \-      0.000   0.000                                      0.430                                     0.000                                       0.008                                       0.863                                      0.035                                      0.000                                       0.000
  BMI               \-      1.000   0.646[\*\*](#tf5-2){ref-type="table-fn"}   −0.188[\*](#tf5-1){ref-type="table-fn"}   0.289[\*\*](#tf5-2){ref-type="table-fn"}    −0.111                                      0.292[\*\*](#tf5-2){ref-type="table-fn"}   0.225[\*\*](#tf5-2){ref-type="table-fn"}   0.326[\*\*](#tf5-2){ref-type="table-fn"}    0.054
  *p*-value         \-              0.000                                      0.011                                     0.000                                       0.137                                       0.000                                      0.002                                      0.000                                       0.470
  WC (cm)           \-      \-      1.000                                      −0.155[\*](#tf5-1){ref-type="table-fn"}   0.344[\*\*](#tf5-2){ref-type="table-fn"}    0.008                                       0.343[\*\*](#tf5-2){ref-type="table-fn"}   0.345[\*\*](#tf5-2){ref-type="table-fn"}   0.176[\*](#tf5-1){ref-type="table-fn"}      − 0.007
  *p*-value         \-      \-                                                 0.037                                     0.000                                       0.912                                       0.000                                      0.000                                      0.017                                       0.922
  HDL (mg/dL)       \-      \-      \-                                         1.000                                     −0.336[\*\*](#tf5-2){ref-type="table-fn"}   −0.029                                      −0.104                                     −0.102                                     −0.204[\*\*](#tf5-2){ref-type="table-fn"}   −0.161\*
  *p*-value         \-      \-      \-                                                                                   0.000                                       0.693                                       0.164                                      0.169                                      0.006                                       0.030
  TG (mg/dL)        \-      \-      \-                                         \-                                        1.000                                       −0.006                                      0.053                                      0.168[\*](#tf5-1){ref-type="table-fn"}     0.212[\*\*](#tf5-2){ref-type="table-fn"}    0.161\*
  *p*-value         \-      \-      \-                                         \-                                                                                    0.931                                       0.480                                      0.023                                      0.004                                       0.030
  Glucose (mg/dL)   \-      \-      \-                                         \-                                        \-                                          1.000                                       0.024                                      0.122                                      0.162[\*](#tf5-1){ref-type="table-fn"}      0.184\*
  *p*-value         \-      \-      \-                                         \-                                        \-                                                                                      0.745                                      0.101                                      0.029                                       0.013
  SBP (mmHg)        \-      \-      \-                                         \-                                        \-                                          \-                                          1.000                                      0.474[\*\*](#tf5-2){ref-type="table-fn"}   0.020                                       −0.045
  *p*-value         \-      \-      \-                                         \-                                        \-                                          \-                                                                                     0.000                                      0.790                                       0.548
  DBP (mmHg)        \-      \-      \-                                         \-                                        \-                                          \-                                          \-                                         1.000                                      0.030                                       0.038
  *p*-value         \-      \-      \-                                         \-                                        \-                                          \-                                          \-                                                                                    0.690                                       0.612
  Insulin (μU/mL)   \-      \-      \-                                         \-                                        \-                                          \-                                          \-                                         \-                                         1.000                                       0.411[\*\*](#tf5-2){ref-type="table-fn"}
  *p*-value         \-      \-      \-                                         \-                                        \-                                          \-                                          \-                                         \-                                                                                     0.000

BF, Body fat; DBP, Diastolic Blood pressure; HDL-C, High Density lipoprotein-Cholesterol; IR, Insulin Resistance; SBP, Systolic blood pressure; TG, Triglycerides; WC, Waist circumference.

*p* \< 0.05;

*p* \< 0.01.

Age- and sex-adjusted linear regression analysis showed that all three adiposity markers (BMI, WC and %BF) were significant predictors of TG, Insulin, SBP and DBP (data not shown). Regression analyses also showed that BMI (OR = 1.255; 95% CI = 1.144−1.377), %BF (OR = 1.157; 95% CI = 1.082−1.239) and WC (OR =1.081; 95% CI = 1.044−1.119) were all significant predictors of MS in the study sample.

DISCUSSION
==========

This study is the first, to our knowledge, to examine the association between obesity and MS indicators among adolescents from the *Levant* area in the Middle-East. It showed that obesity increases the risk of developing MS among Lebanese adolescents (13--19 years) of Tanner stages 4--5. The prevalence of MS was estimated at 21.2% in obese adolescents using IDF criteria, with obese boys presenting a higher rate as compared to obese girls. Abdominal obesity, reduced HDL-levels and hypertriglyceridemia appeared as the main abnormalities contributing to the syndrome.

Various definitions of paediatric MS have been used in the literature with varied sets of criteria and different cut-off values for each risk factor, making disparities across studies difficult to appraise ([@b8]; [@b10]; [@b43]; [@b23]). For comparison purposes, the prevalence of MS in this study was re-calculated using the ATP III definition ([@b8]) and results were contrasted with those obtained from the region and elsewhere. Findings indicate that the prevalence of MS among obese adolescents in Lebanon (24%) is notably high, exceeding that reported from developed countries such as Italy (16.5%) ([@b5]) and Spain (18.0%) ([@b30]), while being lower than that reported from the US (42%) ([@b12]), the UAE (44%) ([@b14]) and Iran (41.9%) ([@b15]). This discrepancy in MS prevalence among obese adolescents is in line with the assumptions of an ethnic-based association between obesity and MS indicators. Several studies have suggested that the impact of obesity, particularly abdominal obesity on MS abnormalities may vary by ethnic origin ([@b6]). For instance, a study conducted in Norway documented a considerably higher prevalence of MS among overweight and obese children with Middle Eastern origins as compared to their Norwegian counterparts (30.6% and 20.8%, respectively) ([@b26]). It is in this context that the use of criteria specific to race or ethnic group for MS in youths is becoming highly warranted ([@b39]).

The results of the present study clearly show that the presence of individual cardiometabolic risk factors was high in obese subjects, with 97.1% of obese adolescents presenting with at least one MS abnormality (data not shown). These findings may place obese adolescents at a higher risk for early manifestations of atherosclerosis, as suggested by [@b44], who showed that brachial artery dispensability decreased in obese adolescents as adiposity, IR, diastolic blood pressure and the other criteria of MS increased.

The findings of this study suggest gender disparities in the prevalence of MS, with boys presenting higher prevalence rates as compared to girls. This higher prevalence of MS in boys is in agreement with previous studies conducted in the US ([@b8]; [@b43]), but contradictory to those reported from Iran, another Middle-Eastern country ([@b15]). One reason behind this gender disparity in our study may be the higher prevalence of severe obesity (BMI \> +3 *Z*-scores for sex and age) among boys (8.0%) as compared to girls (5.3%).

In addition to abdominal obesity, which was present in the majority of subjects having the MS, this study showed that low HDL and elevated TG contributed most to MS prevalence (96.2% and 73.1%, respectively). Further analysis of the data by logistic regression showed that the TG/HDL ratio was a strong determinant of MS in the study sample (OR = 4.3, 95% CI = 2.76−6.72). The high prevalence of high TG coupled with low HDL (i.e. a high TG/HDL ratio) among obese subjects has been noted previously as a strong predictor of MS in Venezuelan children (6--12 years) ([@b33]), prompting investigators to propose the use of the TG/HDL ratio as a predictive indicator of MS in children and adolescents ([@b19]; [@b12]; [@b28]). It is worth noting that, in a national study on the prevalence of MS among Lebanese adults, low HDL appeared as the most prevalent metabolic abnormality in the studied population (49.3%) ([@b37]). This is supported by previous findings where reduced HDL levels were reported as the most common metabolic abnormality among adult Arab Americans ([@b21]).

In this study, 73.1% of obese adolescents were hyperinsulinemic and 88.5% insulin-resistant, based on HOMA-IR. These findings are similar to those reported from France ([@b13]) where 71.8% of obese children and adolescents were insulin-resistant, but higher than estimates reported from Bolivia (39.4%) ([@b4]), Italy (40.8%) ([@b42]), Spain (45.4%) ([@b40]) and Mexico (51%) ([@b22]). Hyperinsulinemia serves to compensate for IR to maintain glucose homeostasis ([@b16]), as evidenced by the fact that the least common abnormality in the study subjects was elevated fasting blood glucose. Adolescents with hyperinsulinemia and IR are prone to several health problems, including systemic inflammation, endothelial dysfunction, hypertension, polycystic ovary syndrome and early atherosclerosis, all of which can appear during childhood and adolescence in obese individuals ([@b16]; [@b38]; [@b22]). IR has also been suggested to play a pivotal role in the pathogenesis of MS as evidenced by the fact that, in this study, IR was found in all subjects having MS. This central role of IR in the development of MS is corroborated by results from other studies in American, Mexican and Bolivian youth suggesting that MS is more likely to develop in children and adolescents with hyperinsulinemia ([@b9]; [@b4]; [@b35]; [@b22]). IR has thus been suggested as being a significant predictor of the paediatric MS and was proposed as a diagnostic tool in children and adolescents ([@b41]; [@b27]).

In this study, regression analyses showed that %BF, BMI and WC were relatively similar in their ability to predict MS and that body fat was not superior to either BMI or WC in predicting metabolic risk in obese adolescents. These findings are in agreement with those reported by [@b32] in Swedish adolescents and [@b29] in Pima Indian adolescents, thus underscoring the utility of BMI as an adiposity indicator and a predictor of cardiovascular risk factors in this age group. BMI was suggested by [@b34] as the most important determinant of MS in a study on obese children and adolescents in Turkey, whereby a one-point increase in BMI *Z*-score resulted in a 2-fold increase in the prevalence of MS ([@b34]).

CONCLUSIONS
===========

In conclusion, this study is, to our knowledge, the first in the *Levant* area and in Lebanon to investigate the magnitude of the association between obesity and components of the MS in an adolescent population group. The findings showed that the prevalence of metabolic abnormalities and their clustering into MS increased with obesity and that BMI, WC and %BF were significant predictors of MS in this age group. These findings highlight the importance of early screening for metabolic abnormalities in adolescent obesity and stress the importance of early weight management intervention strategies as the burden of comorbidities may be reversed if health risks are identified and treated early in life ([@b2]).

The results of this study should be considered in light of the following limitations. Elevated WC was determined, as recommended, according to cut-off points specific for Europids due to the unavailability of WC cut-off values specific for our population. Hyperinsulinemia was also identified based on international cut-off points due to the lack of an upper limit of insulin values for Lebanese population. Finally, we have used fasting glucose and insulin values in the HOMA equation to estimate IR, rather than other more accurate techniques such as the euglycemic clamp.
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